# AMSER Case of the Month September 2021

### 72-year-old female presents for annual mammogram

Savannah Gorisek, MS4
Drexel University College of Medicine





Sarah Thomas, DO

Matthew Hartman, MD

Allegheny Health Network



### Patient Presentation

### • HPI:

- Patient presents for clinical breast exam and right breast screening 5 years follow up left IDC s/p mastectomy
- Patient denies palpable findings, nipple discharge, nipple inversion, breast pain, or erythema of the breast

### • PMH:

- Left DCIS s/p partial mastectomy and adjuvant radiation (2009)
- Left IDC (ER-/PR-/HER2-) s/p simple mastectomy and adjuvant chemotherapy (2016)
- Other relevant medical history temporarily withheld



# What imaging should be ordered according to ACR breast cancer screening guidelines?



### ACR Appropriateness Criteria

#### Variant 2:


Breast cancer screening. Intermediate-risk women: women with personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia, or 15% to 20% lifetime risk of breast cancer.

Procedure	Appropriateness Category	Relative Radiation Level
Mammography screening	Usually Appropriate	€€
Digital breast tomosynthesis screening	Usually Appropriate	<b>∵</b>
MRI breast without and with IV contrast	May Be Appropriate	0
US breast	May Be Appropriate	0
FDG-PET breast dedicated	Usually Not Appropriate	❖❖❖❖
Sestamibi MBI	Usually Not Appropriate	���
MRI breast without IV contrast	Usually Not Appropriate	0

This imaging modality was ordered by the primary physician



## Findings (unlabeled) – Screening Mammogram






## Did you spot any interesting skin findings?




# Additional Imaging – Prior CT






# Findings (labeled) – Screening Mammogram





# Additional Imaging (labeled) — Prior CT

Superficial neurofibromas





### Final Diagnosis:

### Neurofibromatosis 1

Final Impression of Screening Mammogram: BI-RADS 2 – Benign



### Case Discussion – Neurofibromatosis 1 (NF1)

- Autosomal dominant multisystem neurocutaneous disorder
- Affects 1:2500-3000 individuals
- Mutation of tumor suppressor gene → loss of function → uninhibited cell growth with neurofibroma development
- Clinical manifestations:
  - Neurofibromas
  - Café au lait spots
  - Lisch nodules
  - Axillary and inguinal freckling

- Skeletal abnormalities
  - Sphenoid wind dysplasia
  - Leg bowing
- Optic nerve glioma



# Teaching Point - Breast radiographic features of neurofibromas in NF1

### **Mammography**

- Well-defined benign-appearing masses
- Classically <u>peri-areolar</u>
- May mimic and partially obscure breast lesions

### **Ultrasound**

- Well-defined hypoechoic masses with posterior acoustic enhancement
- Features similar to fibroadenoma



### References:

- Williams VC, Lucas J, Babcock MA et-al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123 (1): 124-33. <a href="https://doi.org/10.1542/peds.2007-3204">doi:10.1542/peds.2007-3204</a>
- Lu-Emerson C, Plotkin SR. The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009;6 (2): E47-53.
- Hillier JC, Moskovic E. The soft-tissue manifestations of neurofibromatosis type 1. Clin Radiol. 2005;60 (9): 960-7. <a href="https://doi.org/doi:10.1016/j.crad.2005.02.008">doi:10.1016/j.crad.2005.02.008</a>
- Gokalp G, Hakyemez B, Kizilkaya E et-al. Myxoid neurofibromas of the breast: mammographical, sonographical and MRI appearances. Br J Radiol. 2007;80 (958): e234-7. doi:10.1259/bjr/33539044

